Strategic Partnerships GSK US is actively engaging in sustainability and climate initiatives, evidenced by a carbon removal deal with Varaha. This indicates receptivity to partnerships that align with environmental and regulatory compliance goals, presenting opportunities to offer eco-friendly supply chain solutions, renewable energy management, and carbon accounting services.

Vaccine and Therapeutics Expansion GSK maintains a broad portfolio across pharmaceuticals, vaccines, and consumer healthcare, with ongoing development like HMPL-A830 for KRAS-altered tumors. Sales plays could focus on data management, clinical trial analytics, and cloud-based collaboration tools to accelerate research, regulatory submissions, and global manufacturing planning.

Legacy and Growth Markets With a long-standing vaccine footprint in Europe and imminent site closures in Dresden and other Western Europe locations, there is potential for transitions in manufacturing support, plant modernization services, and IT systems consolidation to optimize remaining operations and workforce redeployment.

Digital and Data Enablement GSK’s tech stack leveraging IBM Cognos Analytics, Azure DevOps, MongoDB, and collaboration platforms indicates a reliance on data-driven decision making and scalable development pipelines. Opportunities exist for analytics modernization, data governance, developer productivity tools, and security enhancements across R&D and manufacturing IT environments.

M&A and Licensing Synergy Recent licensing and development activity, including partnerships and external collaborations, signals openness to external tech and life sciences IP. This creates openings for venture investments, co-development platforms, and integration services to support joint ventures and technology transfer.